

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**CSPC PHARMACEUTICAL GROUP LIMITED**  
**石藥集團有限公司**

*(Incorporated in Hong Kong under the Companies Ordinance)*  
**(Stock Code: 1093)**

**VOLUNTARY ANNOUNCEMENT**

**PASSING OF CONSISTENCY EVALUATION  
FOR “WEIHONG” (AZITHROMYCIN TABLETS)**

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the Group’s “**Weihong**” (azithromycin tablets (0.25g and 0.5g)) (the “**Drug**”) has been granted approval by the China Food and Drug Administration for passing the consistency of quality and efficacy evaluation of generic drugs (the “**Consistency Evaluation**”). The Group is the first one passing the Consistency Evaluation for this type of drug in China.

Azithromycin is a macrolides antibiotic mainly used for the treatment of various bacterial infections, including bronchitis, pneumonia, skin and soft tissues infections, otitis media, sinusitis, pharyngitis and tonsillitis. Azithromycin is also used for the treatment of various sexually transmitted infections, including chlamydia infected diseases and gonorrhea.

Azithromycin tablet is one of the key anti-infective drugs of the Group, having the largest market share of the same type of drug in domestic market. The passing of the Consistency Evaluation proves the consistency of the Drug with the originator drug in terms of quality and efficacy, indicating its availability as a clinical alternative for the originator drug and providing a medication option of good quality and competitive price for patients.

By Order of the Board  
**CSPC Pharmaceutical Group Limited**  
**CAI Dongchen**  
*Chairman*

Hong Kong, 12 April 2018

*As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. PAN Weidong, Mr. WANG Huaiyu, Mr. WANG Zhenguo, Mr. WANG Jinxu, Mr. LU Hua, Mr. LI Chunlei and Mr. CHAK Kin Man as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Mr. LO Yuk Lam, Mr. YU Jinming and Mr. CHEN Chuan as independent non-executive directors.*